Skip to main content

Home/ Cancer/ Group items tagged Patients

Rss Feed Group items tagged

Matti Narkia

T-helper/T-regulator lymphocyte ratio as a new immunobiological index to quantify the a... - 0 views

  •  
    T-helper/T-regulator lymphocyte ratio as a new immunobiological index to quantify the anticancer immune status in cancer patients. Brivio F, Fumagalli L, Parolini D, Messina G, Rovelli F, Rescaldani R, Vigore L, Vezzo R, Vaghi M, Di Bella S, Lissoni P. In Vivo. 2008 Sep-Oct;22(5):647-50. PMID: 18853761 RESULTS: The mean TH/TR ratio observed in patients with metasytases was significantly lower with respect to that found in both patients without metastases and controls. On the contrary, the absolute mean number of T-reg cells was higher in patients with metastases than in those without, but the difference was not statistically significant. CONCLUSION: The evaluation of T-reg cells in terms of their proportion with respect to T-helper cell total number seems to be more appropriate than the simple measurement of their absolute count, in order to quantify cancer-related immunosuppression. Thus, the TH/TR ratio could represent a useful biological marker to explore the immune status of cancer patients.
Matti Narkia

Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine F... - 0 views

  •  
    Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features This study is currently recruiting participants. Verified by Neotropix, September 2008 This is the first study in man of Seneca Valley Virus, a virus which seeks and kills certain tumors in non-human model systems. Subjects in this trial will be patients with advanced cancer displaying certain specified neuroendocrine features, pathologically; they will have exhausted standard methods of treatment for their tumor. The primary purpose of the trial is to determine if the virus may be administered safely. Additional purposes are to learn about the distribution of the virus in the body, the elimination of the virus from the body, the immune response to the virus and whether the virus might have some beneficial effects upon the tumors which the patients have. The first patients will be treated with low amounts of virus and subsequent patients may receive higher amounts. At the end of the trial, it is intended to select a dose for further study.
Matti Narkia

A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in brea... - 0 views

  •  
    A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases. Amir E, Simmons CE, Freedman OC, Dranitsaris G, Cole DE, Vieth R, Ooi WS, Clemons M. Cancer. 2009 Nov 13. [Epub ahead of print] PMID: 19918922 DOI: 10.1002/cncr.24749 METHODS: Patients with bone metastases treated with bisphosphonates were enrolled into this single-arm phase 2 study. Patients received 10,000 IU of vitamin D3 and 1000 mg of calcium supplementation each day for 4 months. The effect of this treatment on palliation, bone resorption markers, calcium metabolism, and toxicity were evaluated at baseline and monthly thereafter. CONCLUSIONS: Daily doses of 10,000 IU vitamin D3 for 4 months appear safe in patients without comorbid conditions causing hypersensitivity to vitamin D. Treatment reduced inappropriately elevated parathyroid hormone levels, presumably caused by long-term bisphosphonate use. There did not appear to be a significant palliative benefit nor any significant change in bone resorption. Cancer 2010. © 2009 American Cancer Society.
Matti Narkia

Coriolus versicolor and cancer (June 2003) - 0 views

  •  
    Attached please find the final draft of Dr. Kenyon's non-controlled observational study on the use of Coriolus versicolor (non-extracted) in 30 solid tumour cancer patients. The final report will be published in the February edition of Mycology News 7. The patients were Stage III and Stage IV patients in which chemotherapy and radiotherapy were not considered successful. Below please find a synopsis of patient type.
Matti Narkia

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer - British J... - 1 views

  •  
    Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Michelakis ED, Webster L, Mackey JR. Br J Cancer. 2008 Oct 7;99(7):989-94. Epub 2008 Sep 2. Review. PMID: 18766181 doi:10.1038/sj.bjc.6604554 The unique metabolism of most solid tumours (aerobic glycolysis, i.e., Warburg effect) is not only the basis of diagnosing cancer with metabolic imaging but might also be associated with the resistance to apoptosis that characterises cancer. The glycolytic phenotype in cancer appears to be the common denominator of diverse molecular abnormalities in cancer and may be associated with a (potentially reversible) suppression of mitochondrial function. The generic drug dichloroacetate is an orally available small molecule that, by inhibiting the pyruvate dehydrogenase kinase, increases the flux of pyruvate into the mitochondria, promoting glucose oxidation over glycolysis. This reverses the suppressed mitochondrial apoptosis in cancer and results in suppression of tumour growth in vitro and in vivo. Here, we review the scientific and clinical rationale supporting the rapid translation of this promising metabolic modulator in early-phase cancer clinical trials More than 40 nonrandomised trials of DCA in small cohorts of patients have been reported, but the first two randomised control trials of chronic oral therapy with DCA in congenital mitochondrial diseases were reported in 2006. In the first, a blinded placebo-controlled study was performed with oral DCA administered at 25 mg kg-1 day-1 in 30 patients with MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) (Kaufmann et al, 2006). Most patients enrolled in the DCA arm developed symptomatic peripheral neuropathy, compared with 4 out of 15 in the placebo arm, leading to the termination of the study. Seventeen out of 19 patients had at least partial resolution of peripheral neurological symptoms by 9 months after discontinuation of DCA. This neurotoxicity res
Matti Narkia

ACOR Home Page - 0 views

  •  
    ACOR is an Internet-based public charity dedicated to improve the quality of care provided to cancer patients and the quality of life of patients, survivors and their caregivers. ACOR leverages its wide technological and biomedical resource expertise to be a reliable source of knowledge, support and community in a relentless worldwide campaign to empower those suffering from the disease. ACOR achieves its mission by constantly investing in advanced technologies and improving them to: Provide uninterrupted open access to a large nexus of online peer support groups (Health eCommunities) it creates and manages, Host a number of exceptional patient-centered websites. Conduct breakthrough research.
Matti Narkia

CancerGuide: Steve Dunn's Cancer Information Page - 0 views

  •  
    CancerGuide is a cancer information page written by Steve Dunn, a fellow patient. I strongly believe, and indeed I know from personal experience, that information can save your life. This page is dedicated to helping cancer patients find the best treatment for their disease by finding, and understanding, the best and latest information on their disease. The focus here is on technical information. While this page does offer links to the best cancer information sources on the net, what makes this page special is no holds barred help and information about things on and off the net from someone who's been been where you are now. The information on this page is information with a point of view, not information sanitized by committee!
Matti Narkia

Medicor Cancer Centres - DCA Therapy - 0 views

  •  
    For the first time in the world, on December 7, 2007 we publicly shared our observational data from the treatment of 118 cancer patients with DCA. In March 2008 we updated our data from treating over 175 patients. As of August 2008, we have treated over 265 cancer patients with DCA. Results of the analysis of our latest data are very similar to our two earlier reports.
Matti Narkia

Omega-3 Fatty Acids May Benefit Cancer Patients Undergoing Major Operations - 0 views

  •  
    ScienceDaily (Apr. 10, 2009) - New research from Trinity College Dublin published in this month's Annals of Surgery points to a potentially significant advance in the treatment of patients undergoing major cancer surgery. The study was carried out by the oesophageal research group at Trinity College Dublin and St James's Hospital. A randomised controlled trial showed omega-3 fatty acids given as part of an oral nutritional supplement resulted in the preservation of muscle mass in patients undergoing surgery for oesopahageal cancer, a procedure normally associated with significant weight loss and quality of life issues.
Matti Narkia

Vitamin D Is Associated with Improved Survival in Early-Stage Non-Small Cell Lung Cance... - 0 views

  •  
    Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Zhou W, Suk R, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2303-9. PMID: 16214909 In conclusion, the joint effects of surgery season and recent vitamin D intake seem to be associated with the survival of early-stage non-small cell lung cancer patients.
Matti Narkia

Circulating 25-Hydroxyvitamin D Levels and Survival in Patients With Colorectal Cancer ... - 0 views

  •  
    Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL, Fuchs CS. J Clin Oncol. 2008 Jun 20;26(18):2984-91. PMID: 18565885 DOI: 10.1200/JCO.2007.15.1027 Conclusion Among patients with colorectal cancer, higher prediagnosis plasma 25(OH)D levels were associated with a significant improvement in overall survival. Further study of the vitamin D pathway and its influence on colorectal carcinogenesis and cancer progression is warranted.
1-800-Oncologist

Great Cancer News Resource - 0 views

At 1-800-Oncologist we believe that: -Patient education empowers action; -Patients should be armed with important facts about cancer prevention; -Patients should understand healthy lifestyles that ...

Cancer nutrition study medline research

started by 1-800-Oncologist on 22 Aug 12 no follow-up yet
fifthseason financial

Financial Assistance for Cancer Patients - 0 views

  •  
    Financial assistance for the Cancer Patients. Fifthseasonfinancial.com providing loans for late-stage cancer patients, secured by their life insurance policy.
paijo9

Diet for Breast Cancer Patients | cancerlab.org - 0 views

  •  
    Most breast cancer patients will receive surgery and then need to complete 4-6 cycles of postoperative adjuvant chemotherapy.
Matti Narkia

Cancer Journal: Latest cancer research Larynx-saving chemo combination | ecancermedical... - 0 views

  •  
    Patients with larynx cancer who received a three-drug combination of docetaxel, cisplatin and 5-fluorouracil (TPF) during induction chemotherapy were more likely to retain larynx function than were patients treated with cisplatin and 5-fluoruracil (PF) alone, according to data from a randomized controlled trial in the March 24 online issue of the Journal of the National Cancer Institute.
Matti Narkia

New data on link between cancer and nutrition discussed at European symposium - 0 views

  •  
    European experts in cancer and nutrition are meeting in Zurich, Switzerland late this month to discuss cutting-edge research in one of the most important and fiercely debated topics in cancer prevention: the link between diet and cancer. There is growing evidence that many cancers may be prevented through healthy lifestyle, including a nutritionally balanced diet. In addition, nutritional problems can also have a negative impact on cancer management and the lives of patients. Other presentations will include new data on topics such as: Childhood nutrition and later breast cancer risk The anti-tumour effects of green tea Malnutrition and patient distress in cancer Possible anti-tumour effects of soy extracts in mice Estrogens in beef and cancer risk
Matti Narkia

Vitamin D levels associated with survival in lymphoma patients - 0 views

  •  
    ScienceDaily (Dec. 5, 2009) - A new study has found that the amount of vitamin D in patients being treated for diffuse large B-cell lymphoma was strongly associated with cancer progression and overall survival. The results will be presented at the annual meeting of the American Society of Hematology in New Orleans. Also, several recent reports have concluded that vitamin D deficiency is associated with poor outcomes in other cancers, including breast, colon and head and neck cancer. This is the first study to look at lymphoma outcome.
Tom Scott

Will Americans Get Access to the First Lung Cancer Vaccine? - 0 views

  •  
    Thanks to the U.S. embargo on Cuba, American lung cancer patients have been unable to access a lung cancer vaccine that has been increasing patients' survival rates on the island since 2008.
Matti Narkia

Novel therapy for cancer? from medicineworld.org - 0 views

  •  
    A ground-breaking Canada-wide clinical trial led by Dr. Katherine Borden, at the Institute for Research in Immunology and Cancer (IRIC) of the Universit de Montral, has shown that a common anti-viral drug, ribavirin, can be beneficial in the treatment of cancer patients. Published in the journal Blood (First Edition), the study demonstrates that ribavirin suppresses the activities of the eIF4E gene in patients. This gene is dysregulated in 30 percent of cancers including breast, prostate, head and neck, colon and stomach cancer.
Matti Narkia

Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with ... - 0 views

  •  
    Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with quantitative assessment of tumor-associated lymphocytes. Kelly MD, King J, Cherian M, Dwerryhouse SJ, Finlay IG, Adams WJ, King DW, Lubowski DZ, Morris DL. Cancer. 1999 Apr 15;85(8):1658-63. PMID: 10223557
1 - 20 of 127 Next › Last »
Showing 20 items per page